CLOs on the Move

Canyon Creek Behavioral Health

www.canyoncreekbh.com

 
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Ceres Inc

Ceres Inc is a Newbury Park, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

EZ-MED

EZ-MED is a Pompano Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Integrated Project Services

IPS-Integrated Project Services, LLC is a global leader in developing innovative solutions for the consulting, architecture, engineering, project controls, construction management, and CQV of technically complex facilities worldwide. With technical expertise spanning R&D to pilot-scale to large-scale production, our team specializes in the technology, trends, and regulatory environment to successfully deliver capital projects and improve operations.

Harkness Pharmaceuticals

Harkness Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Akcea Therapeutics

Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. We are driven by knowing that patients depend on us. An affiliate of Ionis Pharmaceuticals and based in Kendall Square, Cambridge, Massachusetts, Akcea was founded with a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced antisense therapeutics. Akcea is derived from the Greek word for value and worth. Something that has akcea (αξία) is not common, but precious and rare. Our name supports the value we are creating for physicians, patients and their families, and other key stakeholders as we seek to commercialize a robust portfolio of development-stage, advanced, antisense therapies for serious cardiometabolic lipid disorders. Our immediate focus is to drive our clinical programs forward through development to commercialization while building on the Isis standards of excellence.